Metabolic Research Unit (KCL, Waterloo Campus)
London, SE1 9NH, United Kingdom
Location status: Recruiting
Location contact
Nur Kamarunzaman, PhD
CONTACT
+44 (0)20 7848 4162 ext. 84162
Zicheng Zhang, PhD
CONTACT
+442078480313 ext. 80313
NCT Number: NCT07599930
This is a clinical trial aimed to investigate if a novel phytochemical and fibre-rich snack can improve perimenopausal symptoms and well-being in perimenopausal women aged 40-55 and not on hormone replacement therapy.
Hypothesis: The investigators hypothesise that the phytochemical and fibre-rich snack will improve perimenopausal symptoms via a gut microbiota mediated mechanism.
Main research questions:
Does eating the snack every day lower menopause symptoms such as hot flushes, night sweats, mood changes, and sleep problems? Does the snack improve mood, stress, anxiety, sleep, and overall quality of life? Does the snack improve the balance of bacteria in the gut, and could this be part of how it helps symptoms?
Interested in participating?
Request Info40 year–55 year
Female
Interventional
Not applicable
London, SE1 9NH, United Kingdom
Location status: Recruiting
Nur Kamarunzaman, PhD
CONTACT
+44 (0)20 7848 4162 ext. 84162
Zicheng Zhang, PhD
CONTACT
+442078480313 ext. 80313
This double-blind, randomised, placebo-controlled crossover trial will assess the effects of daily consumption for 4 weeks of a novel phytochemical- and fibre-rich granola snack created by TulaCode on menopausal symptoms. The effects of the snack will be compared to a calorie-matched placebo snack: a commercially available oat bar low in fibre and polyphenols. The study will also examine the impact of the intervention snack on mood, stress, sleep quality, cognition, depression and anxiety. Participants will be randomly assigned to either the intervention or the placebo snack for 4 weeks followed by a 4-week washout period before crossing over to the alternate snack for another 4 week period. Snacks will be consumed twice daily, and participants will be instructed to maintain their usual diet and physical activity while avoiding additional probiotic, prebiotic, or polyphenol-rich supplements throughout the study.
Participants will attend 4 in-person study visits at King's College London. At baseline, after 4 weeks, after 8 weeks (washout period) and after 12 weeks. Each study visit will take approximately 1 hour. On the day before each study visit, participants will be asked to self-collect their saliva, 24-h urine and stool samples at home, as well as finish a set of online questionnaires, and be fasted for 12 hours prior to their study visit.
Self-collection procedure of participants at home one day before study visits:
On the morning of each study visit day, participants will bring their self-collected saliva, urine, and stool samples. Any Adverse events will be discussed and recorded. Any concomitant medication will be checked by the researchers that may impact on the eligibility criteria and the early completion of the study. Self-collected samples and completed online questionnaires will be checked. Blood pressure, heart rate and anthropometric measurements will be performed, waist-hip circumference will be measured, and fasting blood samples will be collected.
On Visit 1 (baseline), either intervention snack or a calorie-matched placebo snack will be provided to participants, with the amount should be enough for the 4-week study period. On Visit 3 (after 8 weeks), the crossover snacks will be provided to participants.
At the end of visit 1, 2 and 3, new self-collection kits and a link of online questionnaires will be distributed to participants to be used for next study visit.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A type of phytochemical and fibre rich snack that created and produced by TulaCode called Cinnamon Granola Bark (50 g per pouch). The snack contains the following ingredients: Amaranth, coconut flakes, chia seeds, pumpkin seeds, sunflower seeds, pecans, brazil nuts, almonds, dates, banana, cold pressed extra virgin olive oil, 100% cocoa mass, cocoa butter, chicory root fibre, cinnamon, cloves, nutmeg, ginger, ground vanilla pod, natural Bourbon vanilla flavouring, salt
A type of calorie-matched commercially available chocolate snack, Mini Cornflake Cluster Bites (50 g per pouch). The snack contains the following ingredients: Milk chocolate (60%) (sugar, cocoa butter, cocoa mass, skimmed milk powder, milk fat, lactose (milk), emulsifier (soya lecithin)), corn flakes (40%) (maize, sugar, salt, barley malt extract, dextrose, niacin, iron, vitamin B6, riboflavin, vitamin B1, folic acid, vitamin B12)
Time frame: Baseline & 4 weeks
To assess menopause-related symptoms of perimenopausal women, using the menopause rating scale (MRS). The scale consists in 11 items ranging from 0 (none) to 4 (very severe).
Time frame: Baseline & 4 weeks
The subjective stress level of perimenopausal women are assessed using the Perceived Stress Scale (PSS) questionnaire. The scale consists in 10 items rated on a 5-point Likert scale.
Time frame: Baseline & 4 weeks
To assess the affect of perimenopausal women, using the Positive and Negative Affect Schedule (PANAS-SF) questionnaire, consisting of 20 items rated from 1 (very slightly or not at all) to 5 (extremely).
Time frame: Baseline & 4 weeks
To assess the female sex hormone levels of perimenopausal women, measured several esterone levels in blood samples using the randox clinical biochemistry analyser.
Time frame: Baseline & 4 weeks
To assess cognitive function of perimenopausal womenm using Cognitive Failures questionnaire (CFQ). The questionnaire consists of 25 questions rated on a 5-point Likert scale from 0 ("Never") to 4 ("Very often").
Time frame: Baseline & 4 weeks
To assess the metabolites related to mental health and wellbeing of perimenopausal women, measured a pack of metabolites/compounds including gut-brain axis metabolites, inflammatory markers, short-chain fatty acid, in plasma samples using Randox clinical biochemistry analyser and LC-MS.
Time frame: Baseline only
Habitual diet is assessed via the food frequency questionnaire (FFQ), items ranging from "never" to "multiple times a day"-they consumed specific food and beverage items from a predefined list
Time frame: Baseline & 4 weeks
To investigate the role of the gut microbiome on the perimenopause symptoms. Gut microbiome diversity and composition will be analysed using 16s RNA sequencing technique as a pack.
Time frame: Baseline & 4 weeks
Stress measured as the cortisol level changes in saliva samples by LC-MS, including the cortisol levels at 0 min, 15 min, 30 min and 60 min after wakening and 12 pm and 8 pm on the day.
Time frame: Baseline & 4 weeks
To assess the overall changes in mood, using the Hospital Anxiety and Depression Scale (HADS), consist of 14 items rated on a 0-21 scale, with a higher score indicates a severe symptom.
Time frame: Weekly from baseline to 4 weeks
Sleep quality changes measured using Pittsburgh Sleep Quality Index (PSQI) questionnaire, consist of 19 items rated on a 0-3 scale with higher scores indicating poorer sleep quality.
Time frame: Weekly from baseline to 4 weeks
Changes in physical activity measured using the International Physical Activity questionnaire (IPAQ), producing a total activity score expressed in metabolic equivalent minutes per week (MET-min/week).
Time frame: Baseline & 4 weeks
Changes in quality of life measured using the World Health Organisation Quality of Life Assessment Instrument (EF-WHOQOL-100), a 100 item questionnaire with responses rated on a 1-5 Likert scale
Time frame: Weekly from baseline to 4 weeks
Changes in the gastrointestinal function measured using Gastrointestinal Symptom Rating Scale (GSRS) questionnaire, consisting of 15 items rated from 1 (no discomfort) to 7 (very severe discomfort).
Time frame: Baseline & 4 weeks
Weight will be measured in kilograms using a body composition analyser (Tanita BC-418 MA)
Time frame: Baseline
Height in centimeters will be measured using a stadiometer
Time frame: Baseline & 4 weeks
Changes in BMI will be measured by weighing participants using the body composition analyser (Tanita BC-418 MA) and calculating BMI from participant height and weight
Time frame: Baseline & 4 weeks
Hip and waist circumference will be measured in centimeters using a measuring tape
Time frame: Baseline & 4 weeks
Blood pressure will be measured using an electric sphygmomanometer blood pressure monitor in millimeters of mercury (mmHg).
Time frame: Baseline & 4 weeks
Heart rate will be measured in beats per minute using an electric sphygmomanometer blood pressure monitor
Time frame: Baseline
Polyphenol intake measured via the Food-Frequency Questionnaire - Polyphenol. Food items are rated from "Never" to "More than 6 times per day".
Time frame: Weekly from baseline to week 4
Weekly diet using Intake24, an online 24-hour dietary recall system that records all foods and drinks consumed during the previous day. It uses portion-size images and structured prompts to improve accuracy and reduce under-reporting.
Time frame: Weekly from baseline to week 4
Weekly diet will be measured using OPIS, a mobile application using artificial intelligence to estimate the nutrients and components of meals. Participants take a picture of their meals for 24 hours in the application and AI breaks down the make-up of the food.
Time frame: Baseline and 4 weeks
In total more than 160 phenolic compounds and phase 2 metabolites will be measured in plasma and urine samples by LC-MS.
Contact information is provided by the study sponsor or research team.
Ana Rodriguez-Mateos, PhD
CONTACT
+44 (0)20 7848 4349 ext. 84349
Zicheng Zhang, PhD
CONTACT
+44 (0)20 7848 0313 ext. 80313
King's College London
Other
Impact of a Novel Functional Snack on Perimenopausal Symptoms and Well-being: a Randomised, Double-blinded, Placebo-controlled, Crossover Trial
Acronym: SWAP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07511660
Adnexal Diseases, Cell Therapy
Monterrey, Nuevo León, Mexico
View Trial DetailsNCT07590999
Emotional Processing and Cognitive Function in Perimenopausal Women Experiencing Cognitive Perturbations, Perimenopausal Women
Oxford, England, United Kingdom
View Trial DetailsNCT07695376
Artificial Intelligence (Al), Cardiovascular (CV) Risk
Bogotá, Colombia
View Trial DetailsNCT07688720
Depressive Disorder, Menstruation Disturbances
Fort Worth, Texas, United States
View Trial Details